Targeting undruggable oncoproteins c-Myc and N-Myc by the 9aaTADs

KNIGHT, Andrea, Josef HOUSER, Vilém JURÁŇ, Václav VYBÍHAL, Pavel FADRUS, Martin SMRČKA and Martin PISKÁČEK. Targeting undruggable oncoproteins c-Myc and N-Myc by the 9aaTADs. In Advanced Therapies 2023, 14-15 March 2023, ExCeL, London. 2023.

Basic information

• Original name: Targeting undruggable oncoproteins c-Myc and N-Myc by the 9aaTADs
• Authors: KNIGHT, Andrea (203 Czech Republic, guarantor, belonging to the institution), Josef HOUSER (203 Czech Republic, belonging to the institution), Vilém JURÁŇ (203 Czech Republic, belonging to the institution), Václav VYBÍHAL (203 Czech Republic, belonging to the institution), Pavel FADRUS (203 Czech Republic, belonging to the institution), Martin SMRČKA (203 Czech Republic, belonging to the institution) and Martin PISKÁČEK (40 Austria, belonging to the institution).
• Edition: Advanced Therapies 2023, 14-15 March 2023, ExCeL, London, 2023.

Other information

• Original language: English
• Type of outcome: Presentations at conferences
• Field of Study: 30109 Pathology
• Country of publisher: United Kingdom of Great Britain and Northern Ireland
• Confidentiality degree: is not subject to a state or trade secret
• RIV identification code: RIV/00216224:14110/23:00130478
• Organization unit: Faculty of Medicine
• Keywords in English: c-Myc; N-Myc; 9aaTADs
• Tags: rivok
• Tags: International impact

Abstract

Targeting undruggable oncoproteins c-Myc and N-Myc by the 9aaTADs - Advanced Therapies 2023, 14-15 March 2023, ExCeL, London conference poster.

Links

• LM2018127, research and development project: Name: Česká infrastruktura pro integrativní strukturní biologii (Acronym: CIISB)

Investor: Ministry of Education, Youth and Sports of the CR

• NV19-05-00410, research and development project: Name: Úloha cytotoxických gamma-delta T buněk na terapeutické rezistenci a recidivě Glioblastoma Multiforme

Investor: Ministry of Health of the CR